A 2018 Korean study of 61 patients with advanced GC who were treated with pembrolizumab reported that the objective response rate was significantly higher in PD-L1 (+) patients than in PD-L1 (−) patients (50% vs 0%).[10] Notably, 6 patients with EBVaGC achieved an objective response rate of 100% after immunotherapy. Here, CD274 is linked to gastric cancer.